retatrutide type 2 diabetes trial results Effects of on body composition in people with diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised New GLP-3 drug significantly slashes

Research Considerations Dosing Protocols: In phase 2 trials, doses ranged from 1 mg to 12 mg weekly, with escalation schedules (e.g., starting at 2 mg, increasing to 4 mg, 8 mg, or 12 mg over weeks)

This is why buying from brands that provide clear labelling and third-party testing matters: it is the main quality check available to consumers in the absence of pre-approval

The incidence of prediabetes or T2DM was 10-fold lower (14.3% versus 1.4%) and 3-fold more participants stopped antihypertensive medication (26.0% versus 8.2%) in the semaglutide arm

Paluch AE, Boyer WR, Franklin BA, Laddu D, Lobelo F, Lee DC, et al

The pivotal Phase 2 trial a 48-week study published in The New England Journal of Medicine in 2023 produced these results in adults with obesity (and no diabetes), at the highest dose of 12 mg weekly: Average weight loss of around 24% from baseline A clear dose-response, with even the 4 mg dose producing roughly 17% weight loss Continued weight loss right up to the 48-week endpoint, with no plateau in sight For context, similar Phase 2 data for Wegovy showed around 15% weight loss at 68 weeks

Trulicity Daily injections: Saxenda (liraglutide)